A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS).

Trial Profile

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ALLEGRO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 21 Apr 2016 Post-hoc analysis results (n=1990) (for this data was pooled from ALLEGRO and BRAVO trials) from this and BRAVO trials presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results from ALLEGRO and BRAVO trials at 10 years presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results of a pooled analysis from ALLEGRO and BRAVO trials presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top